<DOC>
	<DOCNO>NCT02018393</DOCNO>
	<brief_summary>This study aim evaluate immunomodulatory effect FEIBA® patient severe haemophilia A inhibitor .</brief_summary>
	<brief_title>Case-control Pilot Study Immune Modulating Effect FEIBA Patients With Haemophilia A Inhibitors</brief_title>
	<detailed_description>This observational , multicentric , case-control one-single-visit study patient severe haemophilia A inhibitor FVIII therapy FEIBA® . Two subject group include : Group 1 ( case ) compose patient severe haemophilia A inhibitor prophylaxis FEIBA® ; Group 2 ( control ) compose patient severe haemophilia A inhibitor on-demand treatment FEIBA® .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<criteria>1 . The subject sign date Informed Consent form participation study . 2 . Age ≥ 18 year old . 3 . Patient severe haemophilia A ( FVIII &lt; 1 % ) highresponding inhibitor ( titre &gt; 5 UB ) point life , currently therapy FEIBA® control bleed . 4 . Group 1 : Patients prophylaxis FEIBA® : The patient prophylaxis regimen FEIBA® least 6 month prior study visit . Group 2 : Patients ondemand regimen FEIBA® : The patient ondemand treatment FEIBA® 6 month prior study visit . 1 . The presence inflammatory condition time study visit previous 30 day , accord medical criterion , would affect study objective . 2 . The patient immune tolerance treatment time 30 day prior study visit . 3 . The administration antiinflammatory immunosuppressive drug 15 day study visit . 4 . Levels CD4 &lt; 200/l regardless HIV status . 5 . Altered hepatic renal function define presence abnormal level alanine aminotransferase ( ALAT ) serum creatinine , respectively . 6 . Administration haemostatic treatment control bleed within 5 day prior study visit .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>FEIBA®</keyword>
</DOC>